Cellebrite Stock: Rating Downgrade As Valuation Has Caught Up (NASDAQ:CLBT)

4 mins read
35 views

Summary

A brief update from my last coverage (11th July): I gave Cellebrite (NASDAQ:CLBT) a buy rating as the business’s strong competitive advantage, mission-critical function, and great execution convinced me that it can continue to grow at 20%. In

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

RFK Jr.’s long history of attacking Trump melted away after he endorsed him for president

Next Story

Care.com to refund $8.5M to customers for its ‘deceptive’ practices, FTC says

Latest from News